Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomatarum I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Sharma R. The burden of prostate cancer is associated with human development index: evidence from 87 countries, 1990-2016. EPMA J. 2019;10:137–52.

Article  ADS  PubMed  PubMed Central  Google Scholar 

Chen S, Cao Z, Prettner K, Kuhn M, Yang J, Jiao L, et al. Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050. JAMA Oncol. 2023;9:465–72.

Article  PubMed  PubMed Central  Google Scholar 

Eastham J, Auffenberg G, Barocas D, Chou R, Crispino T, Davis J, et al. Clinically localized prostate cancer: AUA/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management. J Urol. 2022;208:10–18.

Article  PubMed  Google Scholar 

Mottet N, Cornford P, van den Berg R, Briers E, De Santis M, Gillessen S, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79:243–62.

National Institute for Health and Care Excellence (2022). Prostate cancer: diagnosis and management (NG131). Last updated 15 December 2021.

King M, Keyes M, Frank S, Crook J, Butler W, Rossi P, et al. Low dose rate brachytherapy for primary treatment of localized prostate cancer: asystemic review and executive summary of an evidence-based consensus statement. Brachytherapy. 2021;20:1114–29.

Article  PubMed  Google Scholar 

Hamdy F, Donovan J, Lane J, Metcalfe C, David M, Turner E, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N. Engl J Med. 2023;388:1547–58.

Article  PubMed  Google Scholar 

Donovan J, Hamdy F, Athene Lane J, Mason M, Metcalfe C, Walsh E, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N. Engl J Med. 2016;375:1425–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Skowronek J. Current status of brachytherapy in cancer treatment—a short overview. J Contemp Brachytherapy. 2017;9:581–9.

Article  PubMed  PubMed Central  Google Scholar 

Ragde H, Grado G, Nadir B, Elgamal AA. Modern prostate brachytherapy. CA Cancer J Clin. 2000;50:380–93.

Article  CAS  PubMed  Google Scholar 

Schlussel Markovic E, Buckstein M, Stone N, Stock R. Outcomes and toxicities in patients with intermediate risk prostate cancer treated with brachytherapy alone or brachytherapy and supplemental external beam radiation therapy. BJU Int. 2018;121:774–80.

Article  CAS  PubMed  Google Scholar 

Chargari C, Deutsch E, Blanchard P, Gouy S, Martelli H, Guérin F, et al. Brachytherapy: an overview for clinicians. CA Cancer J Clin. 2019;69:386–401.

Article  PubMed  Google Scholar 

Oh J, Tyldesley S, Pai H, McKenzie M, Halperin R, Duncan G, et al. An updated analysis of the survival endpoints of ASCENDE-RT. Int J Radiat Oncol Biol Phys 2023;115:1061–70.

Article  PubMed  Google Scholar 

Vu C, Jawad M, Krauss D. The cost-effectiveness and value proposition of brachytherapy. Semin Radiat Oncol. 2020;30:87–93.

Article  PubMed  Google Scholar 

Williams V, Kahn J, Thaker N, Beriwal S, Nguyen P, Arthur D, et al. The case for brachytherapy: why it deserves a renaissance. Adv Radiat Oncol. 2021;6:100605.

Article  PubMed  Google Scholar 

Teisberg E, Wallace S, O’Hara S. Defining and implementing value-based health care: a strategic framework. Acad Med. 2020;95:682–5.

Article  PubMed  Google Scholar 

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

Article  PubMed  PubMed Central  Google Scholar 

Prospero. Low-dose-rate brachytherapy as a primary treatment for localised and locally advanced prostate cancer: a systematic review of economic evaluations. National Institute for Health Research 2023. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023442027.

Mathes T, Walgenbach M, Antione S-L, Pieper D, Eikermann M. Methods for systematic reviews of health economic evaluations: a systematic review, comparison, and synthesis of method literature. Med Decis Mak. 2014;34:826–40.

Article  Google Scholar 

Tufts Medical Center—Center for the Evaluation of Value and Risk in Health. https://cevr.tuftsmedicalcenter.org/databases/cea-registry.

National Institute for Health and Care Excellence (2022). NICE health technology evaluations: the manual (PMG36). Last updated 31 October 2023.

Drummond M, Jefferson T. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ. 1996;313:275–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Frederix G. Check your checklist: the dangers of over- and underestimating the quality of economic evaluations. Pharmacoecon Open. 2019;3:433–5.

Article  PubMed  PubMed Central  Google Scholar 

Kato T, Yokomizo A, Matsumoto R, Tohi Y, Miyakawa J, Mitsuzuka K, et al. Comparison on the medical costs between active surveillance and other treatment for early prostate cancer in Japan: from the data of PRAIS-JAPAN study. Int J Urol. 2022;29:1271–8.

Article  CAS  PubMed  Google Scholar 

Eldefrawy A, Katkoori D, Abramowitz M, Soloway M, Manoharan M. Active surveillance vs. treatment for low-risk prostate cancer: a cost comparison. Urol Oncol. 2013;31:576–80.

Article  PubMed  Google Scholar 

Hayes J, Ollendorf D, Pearson S, Barry M, Kantoff P, Lee P, et al. Observation versus initial treatment for men with localised, low-risk prostate cancer: a cost-effectiveness analysis. Ann Intern Med. 2013;158:853–60.

Article  PubMed  PubMed Central  Google Scholar 

Laviana A, Ilg A, Veruttipong D, Tan H-J, Burke M, Niedzwiecki D, et al. Utilising time-driven activity-based costing to understand the short- and long-term costs of treating localised, low-risk prostate cancer. Cancer. 2016;122:447–55.

Article  PubMed  Google Scholar 

Keegan K, Dall’Era M, Durbin-Johnson B, Evans C. Active surveillance for prostate cancer compared with immediate treatment: an economic analysis. Cancer. 2012;118:3512–8.

Article  PubMed  Google Scholar 

Weng X, Zhong L, Xiang P, Li Y, Paciorek A, Dong L, et al. Cost-effectiveness analysis of primary treatments for localised prostate cancer: a population-based Markov analysis using real-world evidence. Eur J Cancer Care. 2022;31:e13740.

Article  Google Scholar 

Cooperberg M, Ramakrishna N, Duff S, Hughes K, Sadownik S, Smith J, et al. Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis. BJU Int. 2013;111:437–50.

Article  PubMed  Google Scholar 

Becerra Bachino V, Cots F, Guedea F, Pera J, Boladeras A, Aguiló F, et al. Cost comparison of three treatments for localised prostate cancer in Spain: radical prostatectomy, prostate brachytherapy and external 3D conformal radiotherapy. Gac Sanit. 2011;25:35–43.

Article  PubMed  Google Scholar 

Satoh T, Ishiyama H, Matsumoto K, Tabata K-I, Kitano M, Iwamura M, et al. Cost comparison of curative therapies for localised prostate cancer in Japan: a single-institution experience. Jpn J Radio. 2009;27:348–54.

Article  Google Scholar 

Shah C, Lanni T, Ghilezan M, Gustafson G, Marvin K, Ye H, et al. Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer. Brachytherapy. 2012;11:441–5.

Article  PubMed  Google Scholar 

Ilg A, Laviana A, Kamrava M, Veruttipong D, Steinberg M, Par S-J, et al. Time-driven activity-based costing of low-dose-rate and high-dose-rate brachytherapy for low-risk prostate cancer. Brachytherapy. 2016;15:760–7.

Article  PubMed  Google Scholar 

Helou J, Torres S, Musunuru H, Raphael J, Cheung P, Vesprini D, et al. Stereotactic body radiotherapy versus low dose rate brachytherapy for localised prostate cancer: a cost-utility analysis. Clin Oncol (R Coll Radio). 2017;29:718–31.

Article  CAS  Google Scholar 

Kowalchuk R, Kim H, Harmsen W, Jeans E, Morris L, Mullikin T, et al. Cost effectiveness of treatment strategies for high risk prostate cancer. Cancer. 2022;128:3815–23.

Article  PubMed  Google Scholar 

Alyamani N, Song J, van Katwyk S, Thavorn K, Renaud J, Haddad A, et al. Cost-utility analysis of radiation treatment modalities for intermediate-risk prostate cancer. Curr Oncol. 2021;28:2385–98.

Article  PubMed  PubMed Central  Google Scholar 

Filson C. Quality of care and economic considerations of active surveillance of men with prostate cancer. Transl Androl Urol. 2018;7:203–13.

Article  PubMed  PubMed Central  Google Scholar 

Noble S, Garfield K, Athene Lane J, Metcalfe C, Davis M, Walsh E, et al. The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer. Br J Cancer. 2020;123:1063–70.

Article  PubMed  PubMed Central  Google Scholar 

Degeling K, Corcoran N, Pereira-Salgado A, Hamid A, Siva S, IJzerman M. Lifetime health and economic outcomes of active surveillance, radical prostatectomy, and radiotherapy for favourable-risk localised prostate cancer. Value Health. 2021;24:1737–45.

Article  PubMed  Google Scholar 

Grummet J, Gorin M, Popert R, O’Brien T, Lamb A, Hadaschik B, et al. “TREXIT 2020”: why the time to abandon transrectal prostate biopsy starts now. Prostate Cancer Prostatic Dis 2020;23:62–65.

Article  PubMed  PubMed Central